SELLAS Life Sciences Group, Inc. — Director's Dealing 2014

Sep 18, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2014-09-16

Reporting Person: SCHWARTZ MARK W. (Director, President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-09-16	Stock Option (right to buy)	$2.23	A	200000	Acquired	2024-09-16	Common Stock (200000)	Direct

Footnotes

F1: Granted pursuant to the Issuer's Amended and Restated 2007 Incentive Plan.

F2: The option will vest in 12 equal quarterly installments over three years beginning on August 21, 2014 (the retroactive effective date of the Reporting Person's employment agreement), provided, in each case, that the Reporting Person remains in continuous employ of the Issuer through such quarterly vesting date.